Attenuation of Nicotine Effects on A549 Lung Cancer Cells by Synthetic α7 nAChR Antagonists APS7-2 and APS8-2

Area of Science:

• Pharmacology
• Oncology
• Neuroscience

Background:

• Nicotine promotes cancer growth and chemotherapy resistance by binding to nicotinic acetylcholine receptors (nAChRs).
• nAChRs are overexpressed in various cancer cells, making them a potential therapeutic target.
• Synthetic analogs of marine toxins offer novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of APS7-2 and APS8-2 as α7 nAChR antagonists.
• To evaluate their efficacy in inhibiting nicotine-mediated effects in A549 human lung cancer cells.
• To assess the cytotoxicity and therapeutic potential of these compounds in lung cancer treatment.

Main Methods:

• Electrophysiological measurements to confirm α7 nAChR antagonism.
• Cytotoxicity assays on A549 lung cancer cells.
• Assessment of nicotine-mediated effects on cell viability, proliferation, intracellular calcium, and reactive oxygen species (ROS) production.
• Evaluation of the compounds' ability to attenuate nicotine-induced effects and enhance cisplatin-induced cytotoxicity.

Main Results:

• APS7-2 and APS8-2 were confirmed as α7 nAChR antagonists.
• APS8-2 demonstrated no cytotoxicity, while APS7-2 exhibited concentration-dependent cytotoxicity in A549 cells.
• APS8-2 effectively attenuated nicotine-mediated increases in cell viability, proliferation, and intracellular calcium.
• APS8-2 reversed nicotine-induced reduction in cisplatin cytotoxicity and ROS production, while APS7-2 was less effective.

Conclusions:

• APS8-2 is a potent α7 nAChR antagonist with significant therapeutic potential in lung cancer chemotherapy.
• The distinct cytotoxic profiles of APS7-2 and APS8-2 highlight the structure-activity relationship in cytotoxicity.
• APS8-2 represents a promising candidate for developing novel lung cancer therapies targeting nicotine-driven pathways.